Loading...
XNAS
BGLC
Market cap7mUSD
Dec 04, Last price  
4.33USD
1D
-1.59%
1Q
-14.09%
IPO
956.10%
Name

BioNexus Gene Lab Corp

Chart & Performance

D1W1MN
XNAS:BGLC chart
P/E
P/S
0.82
EPS
Div Yield, %
Shrs. gr., 5y
-24.36%
Rev. gr., 5y
137.09%
Revenues
10m
-2.66%
0107,680212,328126,95511,390,44013,362,56710,928,7079,770,8069,510,646
Net income
-2m
L-39.20%
-835-123,75026,454-246,4691,094,098751,571-355,966-2,629,043-1,598,342
CFO
-2m
L+71.66%
-835357,216-274,080-217,273552,6809,161544,028-1,301,595-2,234,260

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
IPO date
Mar 11, 2020
Employees
27
Domiciled in
MY
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT